News

LEO Pharma Announces Publication of Head-to-Head DELTA FORCE Study Results in The Lancet
LEO Pharma A/S, a global leader in medical dermatology, is pleased to share that The Lancet, which is considered one of the ...
Fierce Pharma3d
Leo pads case for chronic hand eczema nod with survey showing overwhelming effects on patient lives
More than 90% of dermatology clinicians surveyed by Leo Pharma say their patients with moderate to severe chronic hand eczema ...
pharmaphorum2d
LEO closes on first approval for chronic hand eczema drug
Danish dermatology specialist LEO Pharma could be just weeks away from EU approval for delgocitinib, a treatment for chronic hand eczema (CHE) considered to be its top pipeline prospect.
The Joplin Globe3d
LEO Pharma Survey: Dermatology Providers Agree Chronic Hand Eczema Impacts Patients’ Emotional, Social and Occupational Well-Being
Ninety-five percent (95%) of U.S. dermatology providers surveyed agreed moderate-to-severe chronic hand eczema (CHE) has a strong impact on patients’ work and home life, according to the second phase ...
LEO Pharma A/S: LEO Pharma Announces Publication of Head-to-Head DELTA FORCE Study Results in The Lancet
DELTA FORCE is the first head-to-head phase 3 trial comparing a systemic and investigational delgocitinib topical treatment for Chronic Hand Eczema (CHE).1 LEO Pharma A/S, a global leader in medical ...